Kerri Fitzgerald

Recent and Future Drug Approvals for Important Disease States

11/14/2014

With an influx of blockbuster drugs coming off patent in the next few years, in 2015, a potential $20.9 billion revenue could be reached for first-time generics.

With an influx of blockbuster...

11/14/2014

First Report Managed Care

CATIS Trial on Blood Pressure Reduction

01/21/2014

Kerri Fitzgerald ;

Dallas—Previous clinical trials have found that lowering blood pressure (BP) reduces the risk of stroke in hypertensive and normotensive patients with a history of stroke or transient ischemic attack. However, the effect of antihypertensive...

Dallas—Previous clinical trials...

01/21/2014

First Report Managed Care

News Connection

Postoperative Hyperglycemia Important Risk Factor for SSI

01/17/2011

Kerri Fitzgerald ;

A recent study reported in the Archives of Surgery [2010;145(9):858-864] found that postoperative hyperglycemia is the most important independent risk factor for surgical site infection (SSI) in general surgery patients. Previous studies have...

A recent study reported in the...

01/17/2011

First Report Managed Care

Secukinumab Effective Treatment for Plaque Psoriasis

08/18/2014

Kerri Fitzgerald ;

Previous research has found that interleukin (IL)-17A stimulates keratinocytes to secrete chemokines and other proinflammatory mediators that recruit additional inflammatory cells, thus making IL-17A a master cytokine in the pathogenesis of...

Previous research has found...

08/18/2014

First Report Managed Care

Pain-Related Healthcare Costs

11/26/2012

Kerri Fitzgerald ;

Cincinnati—In the recent past, there have been studies conducted to determine the effects of prior authorization (PA) programs in Medicaid and commercial health plans for Lyrica® (pregabalin). The studies have provided evidence associating...

Cincinnati—In the recent past,...

11/26/2012

First Report Managed Care

News

Improvement of Disease Activity in Patients with PsA with Apremilast

02/17/2015

Kerri Fitzgerald ;

Boston—The results of a recent study indicated that apremilast demonstrated clinically meaningful improvements in psoriatic arthritis (PsA) disease activity measures that were sustained with continual treatment for 52 weeks. Improvements were...

Boston—The results of a recent...

02/17/2015

First Report Managed Care

Comparison of Diabetes Treatment with DPP-4 Inhibitor or Sulfonylurea

05/21/2014

Kerri Fitzgerald ;

Tampa—Diabetes is associated with a sizeable national economic burden. In 2012 dollars, the burden of diagnosed cases in the United States was estimated at $245 billion. Patients with type 2 diabetes mellitus (T2DM)—accounting for 90% to 95%...

Tampa—Diabetes is associated...

05/21/2014

First Report Managed Care

Conference Insider

Multiple Sclerosis Remains a Top Concern for Costly Disease Management

11/14/2014

Kerri Fitzgerald ;

Boston—Multiple sclerosis (MS) is the most common chronic disease affecting the central nervous system in young adults, and it continues to be a costly burden on the healthcare system in terms of treatment options. During a satellite...

Boston—Multiple sclerosis (MS)...

11/14/2014

First Report Managed Care

11/14/2014

Kerri Fitzgerald ;

The first FDA-approved biosimilar agent is expected to hit the market in March 2015; however, there are still a number of questions and concerns.

The first FDA-approved...

11/14/2014

First Report Managed Care

Nonadherence to Statins Impacts Medicare Spending

01/20/2014

Kerri Fitzgerald ;

Medication nonadherence costs the US healthcare system nearly $300 billion annually. Studies have shown that patients who adhere to medication regimens have fewer hospitalizations, lower costs, and lower mortality when compared with...

Medication nonadherence costs...

01/20/2014

First Report Managed Care